The Helicobacter Pylori Eradication in the Group Receiving Standard -dose and Group Continue Taking Amoxicillin for 4 Weeks; a Clinical Trial Study

Overview

Journal Gastroenterol Hepatol Bed Bench

Specialty Gastroenterology

Date 2015 Jul 15

PMID 26171138

Citations 2

Authors

Mohammad Javad Ehsani-Ardakani

Meghdad Sedaghat

Gyti Eslami

Hamid Mohaghegh Shalmani

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of this study was to evaluate the Helicobacter pylori eradication in the group receiving standard -dose twice a day for two weeks and continue taking amoxicillin for 4 weeks.

Background: Helicobacter pylori is the major etiological cause of chronic gastritis, gastric and duodenal ulcers, gastric cancer and lymphoma. Therefore, patients should be treated after diagnosis of H. pylori infection.

Patients And Methods: A total of 66 consecutive patients with rapid urease test during endoscopy or biopsy positive for H. pylori were enrolled in this clinical trial study during 2013-2014. Patients were divided randomly into two groups. Group A (standard dose) received omeprazole (20 mg), amoxicillin (1 g), and clarithromycin (500 mg), all two times a day for two weeks. Group B received standard dose like group A and in patients with H.pylori infection amoxicillin were continued for 4 weeks. After completion of treatment, patients did not receive any treatment for a month and then stool antigen was performed to evaluate the H.pylori.

Results: The rate of successful HP eradication was significantly higher in group A (90.9% V.s 63.6%; p=0.017). Inflation and bitter mouth were found in 8 and 13 patients in group A and 7 and 9 patients in group B, respectively. The incidence of adverse effects was the same (p=0.437).

Conclusion: Increased duration of antibiotic therapy to four weeks significantly raises the rate of successful HP eradication with standard triple therapy without significant increase in adverse effects.

Citing Articles

Eradication of in Iran: A Review.

Fakheri H, Saberi Firoozi M, Bari Z Middle East J Dig Dis. 2018; 10(1):5-17.

PMID: 29682242 PMC: 5903928. DOI: 10.15171/mejdd.2017.84.

Comparison of eradication regimens in patients with end stage renal disease.

Seyyed Majidi M, Sanjari Pirayvatlou P, Rajabikashani M, Firoozabadi M, Seyed Majidi S, Vafaeimanesh J Gastroenterol Hepatol Bed Bench. 2018; 11(1):15-19.

PMID: 29564060 PMC: 5849113.

References

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

Blaser M . Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992; 102(2):720-7. DOI: 10.1016/0016-5085(92)90126-j. View

Marshall B, Warren J . Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390):1311-5. DOI: 10.1016/s0140-6736(84)91816-6. View

Fallone C, Barkun A, Szilagyi A, Herba K, Sewitch M, Martel M . Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol. 2013; 27(7):397-402. PMC: 3956018. DOI: 10.1155/2013/801915. View

Megraud F . Basis for the management of drug-resistant Helicobacter pylori infection. Drugs. 2004; 64(17):1893-904. DOI: 10.2165/00003495-200464170-00003. View

Malfertheiner P, Kirchner T, Kist M, Leodolter A, Peitz U, Strobel S . Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther. 2003; 17(9):1125-35. DOI: 10.1046/j.1365-2036.2003.01560.x. View

Sun W, Ou X, Cao D, Yu Q, Yu T, Hu J . Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. World J Gastroenterol. 2005; 11(16):2477-81. PMC: 4305638. DOI: 10.3748/wjg.v11.i16.2477. View

Yoon H, Kim N, Lee B, Hwang T, Lee D, Park Y . Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter. 2009; 14(5):77-85. DOI: 10.1111/j.1523-5378.2009.00709.x. View

Megraud F . Helicobacter pylori resistance to antibiotics: prevalence, mechanism, detection. What's new?. Can J Gastroenterol. 2003; 17 Suppl B:49B-52B. DOI: 10.1155/2003/704035. View

10.

Wyle F . Helicobacter pylori: current perspectives. J Clin Gastroenterol. 1991; 13 Suppl 1:S114-24. View

11.

Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, MISIUNA P . The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther. 1999; 13(6):703-12. DOI: 10.1046/j.1365-2036.1999.00535.x. View

12.

Luzza F, Imeneo M, Maletta M, Mantelli I, Tancre D, Merando G . Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrol Dial Transplant. 1996; 11(1):120-4. View

13.

Hunt R, Thomson A . Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol. 1998; 12(1):31-41. DOI: 10.1155/1998/170180. View

14.

Romano M, Iovene M, Russo M, Rocco A, Salerno R, Cozzolino D . Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol. 2008; 61(10):1112-5. DOI: 10.1136/jcp.2008.060392. View

15.

Cave D . Transmission and epidemiology of Helicobacter pylori. Am J Med. 1996; 100(5A):12S-17S; discussion 17S-18S. DOI: 10.1016/s0002-9343(96)80224-5. View

16.

Greenberg E, Anderson G, Morgan D, Torres J, Chey W, Bravo L . 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011; 378(9790):507-14. PMC: 3313469. DOI: 10.1016/S0140-6736(11)60825-8. View

17.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K . The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005; 100(5):1037-42. DOI: 10.1111/j.1572-0241.2005.41384.x. View

18.

Malaty H, Graham D, ISAKSSON I, Engstrand L, Pedersen N . Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?. Arch Intern Med. 2000; 160(1):105-9. DOI: 10.1001/archinte.160.1.105. View

19.

Sezer S, Ibis A, Ozdemir B, Ozdemir F, Kulah E, Boyacioglu S . Association of helicobacter pylori infection with nutritional status in hemodialysis patients. Transplant Proc. 2004; 36(1):47-9. DOI: 10.1016/j.transproceed.2003.11.023. View

20.

Bazzoli F, Bianchi Porro G, Bianchi M, Molteni M, Pazzato P, Zagari R . Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis. 2002; 34(1):70-83. DOI: 10.1016/s1590-8658(02)80062-7. View